18880-05-2

Basic information

• Product Name: 3-Methoxybenzyltriphenylphosphonium chloride
• Synonyms: 3-METHOXYBENZYLTRIPHENYLPHOSPHONIUM CHLORIDE;[(3-Methoxyphenyl)methyl]triphenylphosphonium chloride;3-Methoxybenzyltriphenylphosphonium chloride, 98 %;[(3-Methoxyphenyl)Methyl]triphenylphosphaniuM chloride
• CAS NO: 18880-05-2
• Molecular Formula: C₂₆H₂₄OP*Cl
• Molecular Weight: 418.89
• Mol File: 18880-05-2.mol

Chemical Properties

• Melting Point: 271-272 °C
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 3-Methoxybenzyltriphenylphosphonium chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methoxybenzyltriphenylphosphonium chloride(18880-05-2)
• EPA Substance Registry System: 3-Methoxybenzyltriphenylphosphonium chloride(18880-05-2)

Safety Data

• Hazardous Substances Data: 18880-05-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Methoxybenzyltriphenylphosphonium chloride is used as a synthetic intermediate for the production of 2-Hydroxychrysene (H905340), a hydroxylated metabolite of Chrysene (C428000). 3-Methoxybenzyltriphenylphosphonium chloride is relevant in pharmaceutical research due to its binding activity to estrogenic receptors, which can induce toxicity and has potential applications in the development of drugs targeting hormone-related conditions.
Used in Chemical Synthesis:
3-Methoxybenzyltriphenylphosphonium chloride is used as a reagent in the synthesis of various organic compounds, particularly in the preparation of complex organic molecules and pharmaceutical agents. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of a wide range of compounds.

InChI:InChI=1/C26H24OP.ClH/c1-27-23-13-11-12-22(20-23)21-28(24-14-5-2-6-15-24,25-16-7-3-8-17-25)26-18-9-4-10-19-26;/h2-20H,21H2,1H3;1H/q+1;/p-1

Upstream product

• 603-35-0 triphenylphosphine 
• 824-98-6 m-methoxybenzyl chloride 
• 6971-51-3 3-methoxybenzyl alcohol 
• 591-31-1 3-methoxy-benzaldehyde 

Downstream Products

• 82102-27-0 1-methoxy-3-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]benzene 
• 141546-73-8 (E)-(3S,4R)-4-methoxy-6-(4-methoxyphenyl)-3-methylhex-5-enenitrile 
• 69999-70-8 1-Methoxy-3-[(E)-2-((S)-2,6,6-trimethyl-cyclohex-2-enyl)-vinyl]-benzene 
• 168700-28-5 (E/Z)-4-Fluoro-3'-methoxystilbene 
• 354138-94-6 1,3-Dichloro-5-methoxy-2-[(Z)-2-(3-methoxy-phenyl)-vinyl]-benzene 
• 354138-83-3 1,3-Dichloro-5-methoxy-2-[(E)-2-(3-methoxy-phenyl)-vinyl]-benzene 
• 485805-43-4 3-(3-methoxystyryl)-2,4,4-trimethyl-1-cyclohexene 
• 626-20-0 3-methoxystyrene 
• 143212-74-2 1-(2-hydroxyphenyl)-2-(3-methoxyphenyl)ethylene 
• 167145-13-3 2-[2-(3-methoxyphenyl)ethyl]phenol 
• 485805-44-5 3-(3-methoxyphenethyl)-2,4,4-trimethyl-1-cyclohexene 
• 63367-96-4 3-hydroxy-4,3'-dimethoxybibenzyl 
• 1012321-27-5 1-[(E/Z)-2-(3-methoxy)phenylvinyl]-2-nitrobenzene 
• 190264-43-8 2-(3-methoxystyryl)quinoline 

Relevant articles and documents

In vitro study and structure-activity relationship analysis of stilbenoid derivatives as powerful vasorelaxants: Discovery of new lead compound

The development of vasorelaxant as the antihypertensive drug is important as it produces a rapid and direct relaxation effect on the blood vessel muscles. Resveratrol (RV), as the most widely studied stilbenoid and the lead compound, inducing the excellent vasorelaxation effect through the multiple signalling pathways. In this study, the in vitro vascular response of the synthesized trans-stilbenoid derivatives, SB 1-8e were primarily evaluated by employing the phenylephrine (PE)-precontracted endothelium-intact isolated aortic rings. Herein we report trans-3,4,4′-trihydroxystilbene (SB 8b) exhibited surprisingly more than 2-fold improvement to the maximal relaxation (Rmax) of RV. This article also highlights the characterization of the aromatic protons in terms of their unique splitting patterns in 1H NMR.

Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists

Liver X receptor (LXR) agonists are candidates for the treatment of atherosclerosis via induction of ABCA1 (ATP-binding cassette A1) gene expression, which contributes to reverse cholesterol transport (RCT) and to cholesterol efflux from the liver and intestine. However, LXR agonists also induce genes involved in lipogenesis, such as SREBP-1c (sterol regulatory binding element protein 1c) and FAS (fatty acid synthase), thereby causing an undesirable increase in plasma and hepatic triglyceride (TG) levels. Recent studies indicate that LXRα contributes to lipogenesis in liver, and selective LXRβ activation improves RCT in mice. Therefore, LXRβ-selective agonists are promising candidates to improve atherosclerosis without increasing plasma or hepatic TG levels. However, the ligand-binding domains in the two LXR isoforms α/β share high sequence identity, and few LXR ligands show subtype selectivity. In this study we identified a tetrachlorophthalimide analogue as an LXRβ-selective agonist. Structural development led to (E)-4,5,6,7-tetrachloro-2-(2-styrylphenyl)isoindoline-1,3-dione (24 a), which shows potent and selective LXRβ agonistic activity in reporter gene assays. In binding assays, compound 24 a bound to LXRβ preferentially over LXRα. It also induced the expression of ABCA1 mRNA but not SREBP-1c mRNA in cells. Compound 24 a appears to be a promising lead compound for therapeutic agents to treat atherosclerosis without the side effects induced by LXRα/β dual agonists.

Well-defined cyclopropenone-masked dibenzocyclooctyne functionalized polymers from atom transfer radical polymerization

Two functional atom transfer radical polymerization (ATRP) initiators (I-2 and I-3) were developed bearing a cyclopropenone-masked dibenzocyclooctyne group. ATRP was then explored on three main kinds of monomers for radical polymerization including acryla

Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators

Anti-inflammatory effects of liver X receptor (LXR) ligands are thought to be largely due to LXR-mediated transrepression, whereas side effects are caused by activation of LXR-responsive gene expression (transactivation). Therefore, selective LXR modulators that preferentially exhibit transrepression activity should exhibit anti-inflammatory properties with fewer side effects. Here, we synthesized a series of styrylphenylphthalimide analogues and evaluated their structure-activity relationships focusing on LXRs-transactivating-agonistic/antagonistic activities and transrepressional activity. Among the compounds examined, 17l showed potent LXR-transrepressional activity with high selectivity over transactivating activity and did not show characteristic side effects of LXR-transactivating agonists in cells. This representative compound, 17l, was confirmed to have LXR-dependent transrepressional activity and to bind directly to LXRβ. Compound 17l should be useful not only as a chemical tool for studying the biological functions of LXRs transrepression but also as a candidate for a safer agent to treat inflammatory diseases.

SAR study on arylmethyloxyphenyl scaffold: Looking for a P-gp nanomolar affinity

Starting from the previously developed P-gp ligands 1a and 1b (EC 50 = 0.25 μM and 0.65 μM, respectively), new arylmethyloxyphenyl derivatives have been synthesized as P-gp modulators in order to investigate: (i) the effect of small electron-do

Oxidative cyclizations, the synthesis of aryl-substituted c-glycosides, and the role of the second electron transfer step

Anodic oxidation reactions have been used to synthesize aryl- and biaryl-substituted C-glycosides. The reactions take advantage of the tendency for alcohol nucleophiles to trap nonpolar radical cations. The addition of the alcohol to the radical cation appears to be reversible, and the success of the cyclizations is dependent on the ease with which the resulting benzylic radical is oxidized.

Synthesis and structure of styryl-substituted azines

New photochromic derivatives of 2-styrylquinoline and 2-styrylquinoxaline were obtained by the condensation of the methyl derivatives of the mentioned heterocycles with substituted benzaldehydes in the presence of basic and acidic catalysts, and also unde

1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS

The invention relates to a new class of compounds, which are 1-phenylalcoxy-2-β-phenylethyl derivatives, as P-glycoprotein (P-GP) inhibitors. These compounds are useful in drug resistance events. They have been shown able to inhibit in a dose-dependent ma

Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents

Starting from lead compounds 12b and 28b, previously characterized as P-glycoprotein (P-gp) modulating agents, two series of new compounds were investigated. Compounds 14a,b and 15a,b displayed high P-gp modulating activity in the submicromolar range (EC

Arylmethyloxyphenyl derivatives: Small molecules displaying P-glycoprotein inhibition

Some arylmethyloxyphenyl derivatives were prepared as simplified structures of analogous arylpiperazines with high affinity toward dopaminergic D 2 and serotonergic 5-HT1A receptors and inhibiting P-glycoprotein (P-gp). The compounds 5b and 8b displayed good P-gp inhibition activity measured as [3H]vinblastine transport inhibition in the Caco-2 cell monolayer and intracellular doxorubicin accumulation in MCF7/Adr cells by flow cytometry. Compounds 5b and 8b also inhibited, dose-dependently, ATP-ase activation induced by P-gp substrate vinblastine.